Top 50 Life Science VC Funds & Investors in Israel (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Sapir Venture Partners
VC Fund
|
4 | Israel, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, Biotechnology, Machine Learning | $1.3M–$40M |
|
Integra Holdings
VC Fund
|
4 | Israel | Seed, Series B, Series F | Biotechnology, Pharmaceutical, Life Science | |
|
Israel Innovation Authority
VC Fund
|
4 | Israel, United States, Mali | Grant, Seed, Pre-Seed | Health Care, Biotechnology, Medical Device | $130k–$6M |
|
Pitango VC
VC Fund
|
3 | Israel, United States, China | Series A, Series B, Series C | Software, Health Care, Information Technology | $4M–$100M |
|
aMoon Fund
VC Fund
|
3 | United States, Israel, France | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5.7M–$93M |
|
OrbiMed
VC Fund
|
3 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$150M |
|
Grove Ventures
VC Fund
|
3 | Israel, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $3.5M–$74M |
|
First Star Ventures
VC Fund
|
2 | United States, Canada, Israel | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Biotechnology | $575k–$15M |
|
Genesis Park
VC Fund
|
2 | United States, Israel | Private Equity, Debt Financing | Health Care, Construction, Manufacturing | $2.5M–$200M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Takeda Ventures
VC Fund
|
2 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $10M–$130M |
|
Grok Ventures
VC Fund
|
2 | Australia, United States, Singapore | Series A, Seed, Series B | Renewable Energy, Software, Biotechnology | $808k–$150M |
|
Neo Ventures
VC Fund
|
2 | Israel, United States, United Kingdom | Seed, Series A | SaaS, Software, Aerospace | $500k–$24M |
|
Pontifax
VC Fund
|
2 | United States, Israel, France | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.3M–$110M |
|
Minrav
VC Fund
|
2 | Israel, Malaysia | Series A | Health Care, Hospital, Wellness | $10M–$10M |
|
Arancia International
VC Fund
|
2 | Israel, United States, Malaysia | Series A, Series B | Health Care, Biotechnology, Life Science | $7.5M–$17M |
|
PeakBridge
VC Fund
|
2 | Israel, United States, United Kingdom | Series A, Seed, Series B | Food and Beverage, Health Care, Food Processing | $768k–$50M |
|
Johnson & Johnson Robotics and Digital Solutions
VC Fund
|
2 | United States, Israel, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $300k–$100M |
|
Cancer Focus Fund
VC Fund
|
2 | Israel, United States, Germany | Series A, Seed | Biotechnology, Medical, Health Care | $5.4M–$28M |
|
fresh.fund
VC Fund
|
2 | Israel, United States, Norway | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $120k–$21M |
|
FutuRx
VC Fund
|
2 | Israel | Seed | Biotechnology, Life Science, Biopharma | |
|
Bio Capital Impact Fund
VC Fund
|
1 | Israel | Medical, Health Care, Life Science | ||
|
Arba Finance Ltd.
VC Fund
|
1 | Israel | Series A | AgTech, Medical, Cannabis | |
|
ALIVE Israel HealthTech Fund
VC Fund
|
1 | Israel, United States | Series A, Series B | Health Care, Medical, Biotechnology | |
|
Trendlines Group
VC Fund
|
1 | Israel, Singapore, United Kingdom | Seed, Series A | Health Care, Biotechnology, Medical Device | $650k–$15M |
|
OTV
VC Fund
|
1 | United States, Israel, Ghana | Series A, Series B, Seed | Health Care, Medical, Medical Device | $5M–$50M |
|
Forbion Capital Partners
VC Fund
|
1 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $15M–$176M |
|
Sectoral Asset Management
VC Fund
|
1 | United States, United Kingdom, France | Series B, Series C, Post-IPO Equity | Health Care, Biotechnology, Medical | $20M–$230M |
|
HBL Hadasit Bio Holdings
VC Fund
|
1 | Israel | Series A, Series B | Biotechnology, Medical, Health Care | |
|
Arix Bioscience
VC Fund
|
1 | United States, France, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $20M–$140M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
1 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
Aries Holding BV
VC Fund
|
1 | The Netherlands, Israel | Seed, Pre-Seed | FinTech, Finance, Payments | $549k–$3M |
|
Life Science Angels
VC Fund
|
1 | United States, Israel, The Netherlands | Seed, Series A | Biotechnology, Health Care, Medical | $1M–$20M |
|
TPY Capital
VC Fund
|
1 | Israel, United States, France | Seed, Series A, Series B | Software, Artificial Intelligence, Big Data | $3M–$64M |
|
Clal Biotechnology Industries
VC Fund
|
1 | Israel, United States | Series A, Series B | Health Care, Biotechnology, Medical | $4M–$55M |
|
NextLeap Ventures
VC Fund
|
1 | Israel, United States | Seed, Series A | Software, Big Data, Health Care | $900k–$21M |
|
Office of the Chief Scientist
VC Fund
|
1 | Israel | Seed | Health Care, Biotechnology, Hardware | $500k–$1M |
|
RM Global Partners
VC Fund
|
1 | Israel, United States | Series A, Series B | Biotechnology, Health Care, Life Science | $18M–$140M |
|
GoodPaper Ventures
VC Fund
|
1 | Series A | Legal, Legal Tech, E-Signature | ||
|
Jerusalem Venture Partners (JVP)
VC Fund
|
1 | United States, Israel, United Kingdom | Series A, Series B, Seed | Software, Cyber Security, Enterprise Software | $1.5M–$43M |
|
Khosla Ventures
VC Fund
|
1 | United States, India, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Health Care | |
|
SICAR
VC Fund
|
1 | Israel, Germany | Series C | Medical, Health Care, Life Science | |
|
Trust Ventures
VC Fund
|
1 | United States, Brazil, Israel | Seed, Series A, Series B | Health Care, Software, Information Technology | $3.2M–$200M |
|
Talisman Capital Partners
VC Fund
|
1 | United States, Israel, Hong Kong | Series A, Seed, Series B | Information Services, Pet, News | $15M–$63M |
|
Dementia Discovery Fund
VC Fund
|
1 | United States, United Kingdom, Israel | Seed, Series A | Biotechnology, Health Care, Therapeutics | $5.9M–$77M |
|
Rationalwave Capital Partners
VC Fund
|
1 | United States, Israel, Trinidad and Tobago | Seed, Pre-Seed | Analytics, Machine Learning, Artificial Intelligence | $1.3M–$8.8M |
|
3B Future Health Fund
VC Fund
|
1 | United States, Italy, United Kingdom | Series B, Series A | Biotechnology, Therapeutics, Medical | $2.7M–$43M |
|
Milk and Honey Investments
VC Fund
|
1 | Israel | Series A | Life Science, Organic Food, Biotechnology | |
|
Morningside
VC Fund
|
1 | United States, United Kingdom, China | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $6M–$112M |
|
Windham Venture Partners
VC Fund
|
1 | United States, Israel | Series B, Series C, Series A | Health Care, Medical, Medical Device | $4.3M–$100M |
| Access all 101 VC funds in Israel Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Early Stage VC
Show more...Investment focus
- Industry: Software, Biotechnology, Machine Learning
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 20
- Round size: Seed $1.3M–$5M; Series A $10M–$40M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
- Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
- DeepCure — DeepCure is a Boston-based therapeutics company that harnesses advanced AI, physics-based tools and automation to discover novel small molecules for challenging targets. DeepCure currently has a lead asset in IND-enabling studies and other programs focused on drugging intractable targets that have t
Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Life Science
- Stage:Seed, Series B, Series F
- Geography: Israel
Investor stats
- Total investments: 8
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
- Splisense — Transformative RNA Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Pulmonary Diseases Our innovative RNA based therapies, based on Antisense Oligonucleotides (ASOs), restore and modify protein functionality, addressing untreatable pulmonary diseases.
- Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria
The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Grant, Seed, Pre-Seed
- Geography: Israel, United States, Mali
Investor stats
- Total investments: 152
- Round size: Seed $590k–$6M; Grant $130k–$4M; Pre-Seed $150k–$2.5M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Q-Factor —
- Sub-Q Bionics — Sub-Q Bionics is a medtech company, that aids the management of chronic pain and debilitating symptoms of lymphedema specially for women.
- Scala Biodesign — At Scala Biodesign, we provide our partners a unique one-shot computational protein design solutions to dramatically increase the value and accelerate the development of proteins into commercial products.
Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Series B, Series C
- Geography: Israel, United States, China
Investor stats
- Total investments: 280
- Round size: Series A $4M–$50M; Series B $7.5M–$44M; Series C $8.2M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $175M in 2023
Portfolio highlights
- Nas.com — Nas.io helps anyone go from idea to revenue in 1 minute with AI. Create digital products, build engaged communities, and automate marketing—all in one intuitive platform. Nas.io puts community first. Challenges, events, social feed, and memberships drive revenue growth for your business. Join 200k+ entrepreneurs and build your dream digitalbusiness with AI in 1 minute, no technical skills required.
- Nexite — Nexite develops a platform that provides item tracking, inventory transparency and business intelligence from manufacturing to the customer's home. Its miniature NanoBT batteryless tag can be read by any smartphone, costs a fraction of the cost of similar tags, and is small enough to embed into the item. The company was founded in 2017 andis headquartered in Tel Aviv, Israel.
- Sayata — Sayata delivers rapid growth to brokers and carriers that place commercial risk.The Sayata platform streamlines the quote-bind-issue process allowing insurance professionals to seamlessly place commercial risk in a fraction of the time.Sayata provides an end-to-end technological solution along with educational tools, giving our partners theability to grow their book quickly and efficiently.To date, over 1,000 users across 75 brokerages and carriers partner with Sayata to grow their commercial book.
aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 76
- Round size: Series A $5.7M–$83M; Series B $22M–$93M; Series C $30M–$82M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Lin Health — Online chronic pain recovery program designed to get you back to the life you want to live. One-on-one coaching. Real pain reduction results.
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 589
- Round size: Series A $10M–$116M; Series B $24M–$150M; Series C $15M–$143M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Crown Bioscience — Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. Crown Biocience brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases.
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
Grove Ventures is a leading early-stage venture capital fund in Israel. It partners early with exceptional Israeli founders who believe th...
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 70
- Round size: Seed $3.5M–$20M; Series A $8M–$50M; Series B $20M–$74M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- Niv-AI — Niv-AI develops an AI platform that optimizes power usage in AI data centers by capturing real-time electricity consumption data and dynamically balancing workloads. It addresses bottlenecks where synchronized GPUs create sharp power spikes, unlocking up to 30% of stranded capacity without new hardware.
- NoTraffic — NoTraffic has developed the first AI-powered traffic signal platform that connects road...
- Scala Biodesign — At Scala Biodesign, we provide our partners a unique one-shot computational protein design solutions to dramatically increase the value and accelerate the development of proteins into commercial products.
Investing with conviction in visionary, technical founders inventing the future.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 59
- Round size: Seed $1M–$8.5M; Pre-Seed $575k–$1.8M; Series A $4.2M–$15M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- SaolaAI — SaolaAI is the go-to platform for zero-maintenance, maximum-coverage quality, powered by real user behavior insights. With over 30 million user sessions recorded, SaolaAI stands at the forefront of autonomous quality, trusted by hundreds of engineering teams to catch critical issues throughout the application lifecycle, ensuring top-notch productquality with ease.
- Kanary — Established in 2020 by U.S. campaign security and data science experts, Kanary finds, removes, and monitors your information across search engines, data brokers, and social media.
- Blumen Systems — Blumen is an early-stage technology company building software to streamline the regulatory challenges associated with upstream natural resources production in the US. We are focused on producers building and utilizing land-based assets powering the energy transition including carbon sequestration, geothermal, critical minerals, hydrogen, and RNGprojects.
Genesis Park is a Houston-based private equity firm focusing on buyouts, partnering strategies with public corporations, and growth financing. We bring capital, commercial execution capabilities and a depth of experience in mergers and acquisitions.We are opportunistic within market sectors where we have depth and exposure. Those sectors includetelecommunications, energy technology and media. Energy technology is a rapidly expanding category, and our Houston base allows us to marry traditional and alternative techniques in upstream and downstream environments. Founded in 2000, Genesis Park has used discipline and patience to build value for our investors, regardless of prevailing market conditions. We are consistently active in our portfolio companies, listening, learning and adding value by working alongside management. While our preference is to partner with an existing management team, we commonly source additional talent to optimize the existing opportunity.
Show more...Investment focus
- Industry: Health Care, Construction, Manufacturing
- Stage:Private Equity, Debt Financing
- Geography: United States, Israel
Investor stats
- Total investments: 22
- Round size: Debt Financing $5.5M–$65M; Private Equity $2.5M–$200M
- Lead/follow: 59% lead, 41% follow
- Last fund: Likely still investing — raised $275M in 2021
Portfolio highlights
- T&R Recovery Group — T&R Recovery Group offers premier residential therapy for trauma and addiction.
- Chemistry Agency — Chemistry Communications offers social media, media planning/buying, interactive trade show marketing, online marketing, Website design and development, mobile marketing, and package design services.
- GLASS BOX TECHNOLOGY INC — Glass Box Technology Inc offers customizable network, storage, security, and server solutions designed to meet the needs of the industries.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 104
- Round size: Series A $10M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- StrideBio — StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes toovercome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina.
- Xilio Therapeutics — WhatsApp Group Invite
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
Backing a better tomorrow
Show more...Investment focus
- Industry: Renewable Energy, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 66
- Round size: Seed $808k–$10M; Series A $3.3M–$63M; Series B $12M–$150M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Spriggy — Spriggy is a mobile app with a linked prepaid card that helps kids learn the concept of digital money.
- Airwallex — Established in Melbourne in 2015, Airwallex is a global payments fintech that enables businesses to operate anywhere, anytime.In today’s fast-changing digital era, Airwallex's purpose is to empower businesses of all sizes to grow without borders, and by doing so, contribute to the global economy. With technology at its core, Airwallex builta proprietary global financial infrastructure platform to help businesses transact, collect and pay in any foreign currency across 130+ countries and 50+ currencies, without the constraints of the traditional global financial system.
- August Robotics — August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment
Neo Ventures is the first open-ended early stage investor, based in Eastern Europe. The founders have backed more than 30 startups and exited 10 successfully. We invest in game-changing businesses, without geographic limitations. We partner with exceptional founder teams to challenge incumbents in markets ripe for change or to create entirely newmarkets. Neo Ventures funds and then supports the founders in business planning, scaling operations, follow-on investments, making the best of each opportunity and dealing with hard situations. Our investment focus is on data analytics, computer vision and remote sensing addressing disruptive opportunities across the high-growth SpaceTech, BioTech and Security verticals.
Show more...Investment focus
- Industry: SaaS, Software, Aerospace
- Stage:Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 15
- Round size: Seed $500k–$1.7M; Series A $2.3M–$24M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Bulbi — Bulbi is a child development platform designed to help parents discover online and face-to-face educational activities for their children.
- Convex — Convex provides the backend building blocks for your agents. Everything you need to build your full-stack project.
- Cyberwrite — AI-powered cyber insurance intelligence platform that transforms raw data into explainable, defensible financial decisions.
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 111
- Round size: Series A $6.3M–$110M; Series B $20M–$100M; Series C $12M–$104M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $14M in 2020
Portfolio highlights
- Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
Minrav provides engineering and construction services.
Show more...Investment focus
- Industry: Health Care, Hospital, Wellness
- Stage:Series A
- Geography: Israel, Malaysia
Investor stats
- Total investments: 4
- Round size: Series A $10M–$10M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
- Qualitas Health — Qualitas Health Group aims to serve patients through a network of 500 clinics by 2022 with quality healthcare services across the Asia Pacific.
Arancia International Inc is a part of Arancia Group in Mexico. We are long term investors in food, nutrition and biotechnology companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Series A, Series B
- Geography: Israel, United States, Malaysia
Investor stats
- Total investments: 9
- Round size: Series A $10M–$17M; Series B $7.5M–$11M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- NextFerm — NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value.At Nextferm, they aim to use their capabilities to lead this new and exciting world of better nutrition.
- iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
- The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.
PeakBridge is a highly networked, global impact VC that funds and connects the people, technology and processes that will shape the future of food. We invest in visionary pioneers, from early stage to Series A-B, with scalable, protectable climate and health-focused technologies. At their core: a deep commitment to disrupting our food system whiledriving positive impact. Our team is spread across seven countries and includes pioneers of FoodTech investment and decades of deep Agri-Food operational and financial experience. Together, we create exceptional value for bold FoodTech entrepreneurs and investors. A member of the Edmond de Rothschild Private Equity partnership, PeakBridge is also the only venture capital firm that is an official partner of the world’s largest Agri-Food innovation initiative, EIT Food.
Show more...Investment focus
- Industry: Food and Beverage, Health Care, Food Processing
- Stage:Series A, Seed, Series B
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 49
- Round size: Seed $768k–$11M; Series A $4.9M–$17M; Series B $11M–$50M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $106M in 2022
Portfolio highlights
- Mondra — Unlock supply chain intelligence for food system resilience. Discover insights and solutions to build robust and adaptable food supply chains.
- SOUS — One easy-to-use tool to grow traffic, make online sales, seamlessly handle orders and drive retention. Built for food entrepreneurs, built with taste.
- KÄÄPÄ Biotech — Medicinal mushrooms, biotechnology, mycology, forestry, agroforestry, and food production.
Healthcare innovation wherever it originates.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 70
- Round size: Series A $5.9M–$63M; Series B $18M–$55M; Series C $300k–$100M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Moon Surgical — Create the OR of the future, one that is sustainable, efficient, and digitalized.
- Artera — Discover the power of Personalized Precision Medicine & AI Cancer Therapy with Artera. Transforming cancer therapy through innovation.
- ONL Therapeutics — ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Cancer Focus Fund is an oncology-focused investment firm advancing breakthrough cancer therapies by partnering with leading scientists, institutions and early-stage companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: Israel, United States, Germany
Investor stats
- Total investments: 10
- Round size: Series A $5.4M–$28M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $50M in 2019
Portfolio highlights
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of
- Starget Pharma — Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues.
- Nectin Therapeutics — NectinTX develops next-generation delivery platforms for immuno-oncology and precision therapeutics. Discover breakthrough protein expression technologies that power safer, more effective treatments.
fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, Norway
Investor stats
- Total investments: 41
- Round size: Seed $3M–$12M; Pre-Seed $120k–$6M; Series A $11M–$21M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Wisio — Wisio lets social media creators and experts answer questions and requests from followers via paid interactions. The company’s platform empowers followers to gain exclusive access via personalized videos to their favorite creators. Wisio's flexible and easy-to-use platform is packed with features to help creators build deeper communitieswhile monetizing the creator - follower relationship. Thousands of them are already using it to help build their online reputation and business.Wisio's vision is to make everyone reachable.
- Clearitty — Clearitty - The Ultimate Sales Accelerator by Turning Deal Insights into Revenue We provide the tools and insights for sales executives to close deals faster and outperform competitors, empowering you to drive growth and success. It’s free to start — no trial, no contract, no risk.Clearitty was born out of a shared frustration experienced bysales executives and entrepreneurs alike – the lack of critical insights about new buyers. These invaluable insights are often held by those who have successfully navigated the sales process with these coveted clients.Recognizing the gap, in 2022 we created Clearitty, dedicated to developing an intelligence tool that helps sales executives shorten sales cycles and close deals more efficiently.Our goal is to build the world’s largest database of buyer insights, empowering sales executives with the knowledge they need to succeed.
- Sherloq — Ask your SQL anything. Built on your context, directly on your editor.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.
Show more...Investment focus
- Industry: Biotechnology, Life Science, Biopharma
- Stage:Seed
- Geography: Israel
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
- Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
- Bsense Bio Therapeutics — Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety.
Global impact fund focusing on biotech, medtech and agritech investments that make a difference
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Geography: Israel
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
An investment banking boutique, founded in 1978
Show more...Investment focus
- Industry: AgTech, Medical, Cannabis
- Stage:Series A
- Geography: Israel
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- GemmaCert — GemmaCert is a smart solution for testing cannabis potency, which unlike other solutions, is simple and sleek, for everyday use, requiring no specific skill-set for operation, and whose form gives little indication to the sophistication of the technology working underneath. GemmaCert is a bridge between technology and nature. This design createdthe desired attractive and useful man-machine interface for the best possible user experience along with a well-defined product with aesthetic presence without sacrificing on performance. GemmaCert is making a name for high performance, robustness, ease-of-use and reliability.No cannabis flower is the same, so before anyone consumes cannabis, they should have an understanding exactly what is in it and how it may affect them. From pharmacies in Germany, coffeeshops in Amsterdam, to supply chain stakeholders in North America, GemmaCert brings certainty and confidence to cannabis professionals, as well as consumers and patients worldwide.After over two years in research and development, GemmaCert started delivering first units to customers worldwide, primarily in North America and Europe. Revenues are generated from device sales and monthly subscription fees to our analytical service since GemmaCert units are operated and upgraded via secure cloud-based servers.
ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- Wisdo Health — Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health.
- Vessi Medical — Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).
- Gina Life — At Nevia bio, we are focused on women's health. Our mission is to use innovative technologies to provide early detection of diseases through vaginal secretions analysis, enabled by Nevia's Machine Learning Platform.
Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A
- Geography: Israel, Singapore, United Kingdom
Investor stats
- Total investments: 69
- Round size: Seed $650k–$3.2M; Series A $2.3M–$15M
- Lead/follow: 20% lead, 80% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- IBI-Ag — IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Arcuro Medical — Arcuro develops a new repair system for meniscus tears of the knee. Arcuro’s proprietary SuperBall repair system consists of a knotless, all-suture anchor and innovative delivery system. The company was founded in 2013.
OTV focuses on round A+ startups that aim to make a significant impact on people's lives. Our focus is on entrepreneurs with innovative ideas who are advancing the global state of well-being. Come join the digital health revolution, and be a part of transforming the healthcare industry.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: United States, Israel, Ghana
Investor stats
- Total investments: 21
- Round size: Seed $5M–$8M; Series A $6M–$12M; Series B $16M–$50M
- Lead/follow: 57% lead, 43% follow
- Last fund: May invest from a new fund soon — raised $170M in 2020
Portfolio highlights
- Scopio — Buy & sell images on the largest Solana Photography NFT Marketplace. Find high-quality stock images & hire artists from around the world.
- Scopio Labs — Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio's solutions will aim to showcase thousands of cells at scale in high resolution, toenable new hematology diagnostic methods.
- Stake — Renters earn Cash back for rent. Building operators outperform the market. That's the Stake win-win. Find out how we're building the financial tools for the next generation of rentals.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 187
- Round size: Series A $16M–$176M; Series B $15M–$155M; Series C $19M–$113M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Sectoral is specialized in managing equities globally in the healthcare sector. Founded in October 2000, we are SEC-registered as an investment advisor. 100% employee-owned, we have offices in Montreal, Geneva, and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 58
- Round size: Series B $20M–$80M; Series C $39M–$115M; Post-IPO Equity $23M–$230M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Iantrek — Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York.
- CurvaFix — Curvafix is the only intramedullary implant that follows the natural curvature of the pelvis. Continue reading to learn how the Curvafix implant works!
- Magnolia Medical Technologies — Magnolia Medical Technologies, proud makers of the Steripath Micro Initial Specimen Diversion Device for blood culture testing integrity.
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B
- Geography: Israel
Investor stats
- Total investments: 9
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- ProtAb — ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
- Enlivex Therapeutics — Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.
Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, France, Israel
Investor stats
- Total investments: 32
- Round size: Series A $20M–$58M; Series B $45M–$137M; Series C $53M–$140M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Quench Bio — Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enablingpatients to get relief from inflammatory diseases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 98
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
- Centauri Therapeutics — At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.
financial holding company / investments
Show more...Investment focus
- Industry: FinTech, Finance, Payments
- Stage:Seed, Pre-Seed
- Geography: The Netherlands, Israel
Investor stats
- Total investments: 4
- Round size: Seed $2M–$3M; Pre-Seed $549k–$790k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Wakuli — It's called specialty coffee. Roasted lighter to enhance all the exciting flavours. To really taste them it's important to drink fresh. That's why we send our mailbox-friendly coffee within one week after roasting. And always with a better price for the farmers - thanks to you.
- Diptera — Developing technology to fight mosquitoes with mosquitoes.
- Flow — Flow is FinTech 3.0: It let's you automate payments between your bank accounts and wallets. Based on triggers and actions you can transfer your money automatically to the accounts you choose. Use Flow to automate a budgetting system, your investing, buying crypto or to distribute your money the way you like it. Where the previous generationpayment companies needed to build and maintain expensive payment rails, Flow focusses on leveraging Open Banking. People trust Flow to help with their cashflow automation.
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United States, Israel, The Netherlands
Investor stats
- Total investments: 86
- Round size: Seed $1M–$4M; Series A $1.3M–$20M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- ATDev — ATDev provides assistive technology and medical device solutions.
- Journey Live — Journey is shifting the way modern companies prioritize mental health. Our proactive, inclusive tools engage every employee, every day.
- Trio Pharmaceuticals — Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California.
TPY Capital is a Tel Aviv based early state VC, investing in some of Israel’s most talented entrepreneurs. They are active investors who typically lead rounds in the areas we invest in, which include data and analytics, digitization and human augmentation, fintech, and frontier tech such as quantum computing.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Big Data
- Stage:Seed, Series A, Series B
- Geography: Israel, United States, France
Investor stats
- Total investments: 38
- Round size: Seed $3.5M–$24M; Series A $3M–$26M; Series B $9M–$64M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $100M in 2019
Portfolio highlights
- Kooply — Kooply is a team of proven entrepreneurs building a nextgen gaming platform.
- ReturnGO — Easy-to-use self-service return management portal that allows customers to return and exchange products increases revenue and customer retention.
- UNIPaaS Payments Technologies — Own your payment experience, increase customer loyalty and give your business the power to scale.
Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI).
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 14
- Round size: Series A $4M–$55M; Series B $15M–$33M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Sight Diagnostics — Combining AI and breakthrough hardware to bring lab-quality CBC results to the doctor's office.
- Cadent Therapeutics — Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts.
- Elicio Therapeutics — Elicio ground-breaking Amphiphile technology is engineering potent vaccines and immunotherapies to defeat an array of aggressive cancers.
NextLeap Ventures offers investors the opportunity to invest in early stage, Israeli high-tech startups, selected through its unique, highly vetted process.
Show more...Investment focus
- Industry: Software, Big Data, Health Care
- Stage:Seed, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 16
- Round size: Seed $900k–$5M; Series A $5.3M–$21M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Carrar — A complete thermal management solution for electric vehicles dissipating heat faster and more efficiently than ever before. Thermal management for ev batteries.
- Cybord — Cybord develops technologies that stop counterfeit, defective and malicious electronic components from getting assembled into products during the manufacturing process. Cybord scans each component prior to placement by integrating with electronic product manufacturing equipment, and deep learning algorithms rate each component based on Cybord’sglobal component database. Between 5 to 10% of all electronic components are considered counterfeit, responsible for up to 35% of RMAs. With Cybord, OEMs, EMSs, and distributors ensure their products are of high quality and free of hardware-cyber threats
- Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
The Office of the Chief Scientist [OCS] in the Ministry of Economy is charged with execution of government policy for support of industrial R&D. The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel’sscientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high tech entrepreneurship.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Hardware
- Stage:Seed
- Geography: Israel
Investor stats
- Total investments: 4
- Round size: Seed $500k–$1M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- LapSpace — LapSpace Medical was founded in 2011. It operates within the framework of the Misgav Venture Accelerator, part of The Trendines Group. The LapSpace team combines strong business and medical experience and knowledge.
- Sqwik - powered by Geev.Me.Tech LTD — Sqwik is a new way to create, join & follow fun activities, with new friends, within 3 hours.
- Digma Medical — Digma Medical | DiaGone - safe, one-time, 30 minute, minimaly-invasive, GI procedure for Restoring Glycemic Control for T2DM & NASH patients | No Implant
RM Global is an investment banking and strategic advisory firm dedicated to creating unique value for its clients and investors. We specialize in Life Sciences, including pharmaceuticals, medical devices, biotechnology, healthcare IT/digital health, and diagnostics. Our broad international reach includes the Americas, Europe, Israel, and Asia.Since 1992, our diverse team of accomplished professionals has worked closely with life science companies ranging from start-ups to multinationals, providing unbiased strategic and financial advice, based upon our comprehensive industry experience. Several of our partners were senior management of Roberts Mitani, which completed over $3 billion in M&A and strategic transactions and raised over $200 million in private growth and venture capital for clients. We take pride in our long term relationships with our clients that span many years.We leverage our unique global network of leading corporations, investment funds, institutional and strategic investors, family offices, industry experts and management teams to source and execute transactions that build new opportunities for our clients worldwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 4
- Round size: Series A $18M–$20M; Series B $32M–$140M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $64M in 2019
Portfolio highlights
- BIOMx — BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
- Mitoconix Bio — Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism,keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constantly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death.Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).
- ImmPACT Bio — ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
GoodPaper Ventures is a venture capital company that offers private equity and investment management services.
Show more...Investment focus
- Industry: Legal, Legal Tech, E-Signature
- Stage:Series A
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- OneNotary — Looking for a reliable and convenient on-demand online notary service? OneNotary platform offers fully legal and secure notarization services in all 50 states.
- Foresee Genomics — Foresee Genomics brings high-precision NGS to every lab with fast, affordable diagnostics that advance personalized care and unlock growth.
JVP is a top VC firm with $1.9B AUM and 165 companies built, leading in AI, Cyber Security, Fintech, Insurtech and Climatech.
Show more...Investment focus
- Industry: Software, Cyber Security, Enterprise Software
- Stage:Series A, Series B, Seed
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 175
- Round size: Seed $1.5M–$7M; Series A $4.3M–$24M; Series B $10M–$43M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Source Defense — Source Defense provides an entirely new solution, leveraging a fully automated, machine-learning-assisted set of policies that ensure 3rd party JavaScript integrations operating on your website maximize user experience and eliminate the threat of such integrations being leveraged for malicious website activity.
- Pyramid Analytics — The Pyramid Decision Intelligence Platform is built to power faster and sharper decisions. Learn how it can improve your business decisions.
- Greeneye Technology — Spray Less, Grow More. Our mission is to dramatically reduce chemicals usage while increasing productivity and profitability for farmers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 981
- Lead/follow: no public data
Portfolio highlights
- Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
- Vectra AI — Vectra is the world leader in AI threat detection and response. The Cognito platform uses AI to detect attackers in real time and perform conclusive investigations.
- Point One Navigation — Precise Positioning for the next generation of transportation. 10cm accuracy everywhere.
SICAR
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series C
- Geography: Israel, Germany
Investor stats
- Total investments: 2
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Trust Ventures is a venture capital firm that focuses on startups and provides knowledge and expertise in incumbent-heavy industries. The firm was founded in 2018 and is based in Austin, Texas, United States.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Brazil, Israel
Investor stats
- Total investments: 61
- Round size: Seed $3.2M–$23M; Series A $10M–$50M; Series B $9M–$200M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Steno — Built by tech and legal experts, Steno provides a revolutionary approach to court reporting and litigation services.
- StellarFi — We Pay Your Bills, So YouCan Build Credit. With Stellar your bills are paid on time and on your terms.
- Sana Benefits — Does your small business need better health insurance? Get specially designed benefits for employees, including medical, dental, vision & more.
Talisman Capital Partners operates as a private investment company.
Show more...Investment focus
- Industry: Information Services, Pet, News
- Stage:Series A, Seed, Series B
- Geography: United States, Israel, Hong Kong
Investor stats
- Total investments: 7
- Round size: Series A $15M–$63M
- Lead/follow: 57% lead, 43% follow
Portfolio highlights
- Bond Vet — We offer compassionate, thorough, & friendly pet care in a warm, comfortable environment. Walk in or book online.
- Prilenia — Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston.
- qServe Communications — At qServe Communications, it is their unique vision to be a one-stop source for all your maintenance and development needs. They understand the difficulty of locating reliable companies to meet all of your infrastructure requirements. qServe has built an answer to this problem, a national service network of in-house employees to deliver qualitymanagement, installation, erection, inspection and maintenance services to the communications industry.With their full spectrum of project and program management services, they drive your project from start to finish, becoming an integral part of your development team. Many of qServe Communications crews and staff bring many years of valuable experience in the development of communications systems and infrastructures. From Program and Project Management to in-house installation and maintenance services, qServe will work diligently to ensure your project's success.qServe has performed thousands of projects for clients including: AT&T Wireless Services, Alltel Mobile, Nextel, Sprint, Omnipoint, Bell Atlantic Mobile, Teligent, Metricom, American Tower, Crown Castle and SBA Communications Corporation.
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 50
- Round size: Seed $5.9M–$20M; Series A $7M–$77M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $337M in 2018
Portfolio highlights
- Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Rationalwave Capital Partners is a venture capital firm investing in technology companies both public and private. The firm is located in New York and founded by Mark Rosenblatt in 2003.
Show more...Investment focus
- Industry: Analytics, Machine Learning, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: United States, Israel, Trinidad and Tobago
Investor stats
- Total investments: 12
- Round size: Seed $1.3M–$8.8M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Aromyx — Aromyx pioneers the creation of tastes and smells using a quantitative measurement system developed with biotechnology, data science, and AI.
- Brij — With one-touch, BRIJ allows consumers to gain product info, care instructions and discounts while you gain a deeper understanding of your consumer. Apps, paper manuals and hassles not required.
- BactoByte LTD — BactoByte aims to empower caregivers with one-hour bacterial diagnostics and antibiotic screening capability to improve outcomes, reduce mis-diagnostics, and lower health care costs.Based on a proprietary novel basic method, BactoByte’s assay delivers precise and cost-effective identification and direct antibiotics susceptibility testing with80-90% improvement of standard turnaround time.Time reduction, sensitivity, and specificity results in decreased mortality rates, fewer hospital days, and avoidance of associated costs of $1K-50K per patient.BactoByte has technology validation and partnerships with leading medical centers.
Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series B, Series A
- Geography: United States, Italy, United Kingdom
Investor stats
- Total investments: 33
- Round size: Series A $2.7M–$43M; Series B $7.9M–$40M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- Roca Therapeutics — First-in-Class Drugs against ocular diseases driven by hyper-vascularization and immuno-suppressive inflammation.A united team creating an innovative therapy to give a new vision to patients.
- Kainova Therapeutics — Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
The Land of Milk and Honey is an abundant location where life is simple and devoid of need. Both in brand-new real estate development projects and while professionally restoring and renovating houses, Milk and Honey Investments LLC aims to create distinctive spaces of abundance and healthy living.
Show more...Investment focus
- Industry: Life Science, Organic Food, Biotechnology
- Stage:Series A
- Geography: Israel
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- BioBetter — BioBetter is a foodtech company that develops plant-based platforms for the production of complex growth factors used in cultivated meat. The company was founded in 2015 and is headquartered in Israel.
Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically.Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology.Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 106
- Round size: Series A $6M–$45M; Series B $13M–$100M; Series C $9.2M–$112M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Geneoscopy — Geneoscopy is passionate about the work we do, committed to excellence and believes that improvements in personalized medicine can impact the lives of patients...
- Aural Analytics — Powerful brain health analytics that are clinically interpretable, reliable, precise and objective. Award winning and validated by key industry leaders.
- Vesigen Therapeutics — Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes(Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets.
We focus on advances in medical technology and digital health to change the face of healthcare.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series B, Series C, Series A
- Geography: United States, Israel
Investor stats
- Total investments: 61
- Round size: Series A $4.3M–$100M; Series B $7M–$75M; Series C $12M–$73M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- PainTEQ — Explore PainTEQ's innovative solution for SI joint pain. Learn about the LinQ minimally invasive SI joint stabilization procedure, patient success stories, and our commitment to improving quality of life.
- TailorMed — Moving Mountains for Patients
- ClarVista Medical — ClarVista Medical is a developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing, ClarVista was spun out from Prospex Medical, a medical device incubator, to pursue the development of the HARMONI™ IOL. Between 2012 and 2014, the company developed the first generation HARMONI™system, conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system, conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.
Life Science VC funding in Israel at a glance
Stats across 70 deals from 101 investors.
Access all 101 VC funds in Israel Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in Israel investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 101 VC funds investing in Israel Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!